Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1655 1683
This examiner grants 12% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18257233 | Determining the Quantity and Quality of a DNA Library | Non-Final OA | Robert Bosch GmbH |
| 17268941 | DNA AMPLIFICATION METHOD FOR PROBE GENERATION | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 16927641 | Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18410439 | MULTIPLEXED IMAGING USING MERFISH, EXPANSION MICROSCOPY, AND RELATED TECHNOLOGIES | Non-Final OA | President and Fellows of Harvard College |
| 17289889 | NUCLEIC ACID-BASED BARCODING | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 17525336 | Synaptojanin 2 (SYNJ2) Variants And Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18357850 | METHODS AND COMPOSITIONS FOR AMPLIFYING POLYNUCLEOTIDES | Non-Final OA | Singular Genomics Systems, Inc. |
| 17147151 | METHODS OF DETECTING PROGESTERONE RECEPTOR AND OF DETECTING AN EXPRESSION LEVEL | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18343108 | METHODS AND SYSTEMS FOR LIGHT-CONTROLLED SURFACE PATTERNING USING PHOTOMASKS | Non-Final OA | 10x Genomics, Inc. |
| 18120024 | CONCATEMERIC DETECTABLE PROBES AND RELATED METHODS | Non-Final OA | 10x Genomics, Inc. |
| 18021625 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | Final Rejection | The General Hospital Corporation |
| 17513640 | PREDICTING BREAST CANCER RECURRENCE | Final Rejection | The General Hospital Corporation |
| 18758066 | PROTECTING FULLY FUNCTIONAL NUCLEOTIDES FROM DEGRADATION | Non-Final OA | Illumina, Inc. |
| 18507414 | DESIGNING PROBES FOR DEPLETING ABUNDANT TRANSCRIPTS | Non-Final OA | Illumina, Inc. |
| 18476031 | MESOPHILIC COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION | Non-Final OA | Illumina, Inc. |
| 18476151 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | Non-Final OA | ILLUMINA, INC. |
| 18063581 | PARALLEL SAMPLE AND INDEX SEQUENCING | Non-Final OA | Illumina, Inc. |
| 18192147 | METHOD FOR PRODUCING COMPLEX, METHOD FOR DETERMINING MICROBIAL INCLUSION, AND METHOD FOR IDENTIFYING INCLUDED MICROORGANISM | Non-Final OA | Yokogawa Electric Corporation |
| 18745908 | Method and System of Augmenting Cancer Therapy | Non-Final OA | UNIVERSITY OF MIAMI |
| 18040066 | Characterising Macrophages and Methods Thereof | Final Rejection | Agency for Science, Technology and Research |
| 18803758 | Event-Based Sequencing of Nucleic Acids in Real Time | Final Rejection | Stream Genomics, Inc. |
| 18272260 | PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS | Non-Final OA | The Jackson Laboratory |
| 18035319 | MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS | Final Rejection | The Jackson Laboratory |
| 17820559 | METHOD FOR IN VITRO TRANSCRIPTION USING AN IMMOBILIZED RESTRICTION ENZYME | Final Rejection | CureVac AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy